OptiNose (NASDAQ:OPTN) had its target price lowered by BMO Capital Markets from $26.00 to $24.00 in a research report sent to investors on Tuesday morning, BenzingaRatingsTable reports. The brokerage currently has an outperform rating on the stock.
A number of other research analysts have also issued reports on the stock. Zacks Investment Research lowered shares of OptiNose from a buy rating to a hold rating in a report on Thursday, July 11th. ValuEngine upgraded shares of OptiNose from a hold rating to a buy rating in a report on Thursday, August 1st. Piper Jaffray Companies set a $29.00 price objective on shares of OptiNose and gave the company a buy rating in a report on Tuesday, April 23rd. Finally, Cantor Fitzgerald reiterated a buy rating and issued a $27.00 price objective on shares of OptiNose in a report on Thursday, May 9th. One investment analyst has rated the stock with a hold rating and five have given a buy rating to the company. The stock presently has a consensus rating of Buy and a consensus price target of $21.50.
OPTN stock opened at $6.10 on Tuesday. The stock has a market capitalization of $249.47 million, a P/E ratio of -2.28 and a beta of 0.90. The company has a current ratio of 6.60, a quick ratio of 6.74 and a debt-to-equity ratio of 1.06. OptiNose has a 12 month low of $4.44 and a 12 month high of $15.73. The firm has a 50-day moving average price of $6.25 and a 200-day moving average price of $7.98.
Hedge funds and other institutional investors have recently modified their holdings of the stock. UBS Asset Management Americas Inc. bought a new position in shares of OptiNose during the second quarter valued at approximately $72,000. Cubist Systematic Strategies LLC bought a new position in shares of OptiNose during the second quarter valued at approximately $82,000. Bank of America Corp DE raised its holdings in shares of OptiNose by 8.1% during the second quarter. Bank of America Corp DE now owns 105,689 shares of the company’s stock valued at $748,000 after acquiring an additional 7,944 shares in the last quarter. A.R.T. Advisors LLC bought a new position in shares of OptiNose during the second quarter valued at approximately $99,000. Finally, Eversept Partners LP bought a new position in shares of OptiNose during the second quarter valued at approximately $744,000. Institutional investors and hedge funds own 63.78% of the company’s stock.
OptiNose Company Profile
OptiNose, Inc, a specialty pharmaceutical company, focuses on the development and commercialization of products for patients treated by ear, nose, and throat; and allergy specialists in the United States. The company offers XHANCE, a therapeutic product utilizing its proprietary optinose exhalation delivery system that delivers a topically-acting and anti-inflammatory corticosteroid for the treatment of chronic rhinosinusitis with and without nasal polyps.
Receive News & Ratings for OptiNose Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OptiNose and related companies with MarketBeat.com's FREE daily email newsletter.